Technological Advances in Stent Therapies: a Year in Review
- 49 Downloads
Stent technology has rapidly evolved since the first stainless steel bare metal stents with substantial developments in scaffolding, polymer, drug choice, drug delivery, and elution mechanisms. Most recently, there has been the evolution of bioabsorbable vascular scaffolds, potentially eliminating the need for long-term foreign object retention. These rapid developments have led to an ever-expanding selection of new stents, making the choice of which to use in which patient challenging. Operators must balance potential short- and long-term clinical ramifications, namely stent thrombosis, in-stent restenosis, target lesion revascularization, and target lesion failure. In this review, we hope to provide insight for interventional cardiologists on the details of stent technology and how this impacts outcomes, stent selection, and duration of dual-antiplatelet therapy duration post drug-eluting stent implantation.
KeywordsCoronary artery disease Dual-antiplatelet therapy Target lesion failure Target lesion revascularization Stent therapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Smits PC, Vlachojannis GJ, McFadden E, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of Everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE trial (a trial of Everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8(9):1157–65.CrossRefPubMedGoogle Scholar
- 4.Smits PC, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58(1):11–8.CrossRefPubMedGoogle Scholar
- 6.Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an Everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700–8.CrossRefPubMedGoogle Scholar
- 8.Meredith IT, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2017. Advance online publication. Retrieved from http://www.pcronline.com/eurointervention/ahead_of_print/JAA_EIJ_EIJ-D-17-00529. Accessed 11 Nov 2017.
- 10.von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388(10060):2607–17.CrossRefGoogle Scholar
- 12.Sarno G, Lagerqvist B, Olivecrona G, Varenhorst C, Danielewicz M, Hambraeus K, et al. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheter Cardiovasc Interv. 2017;90(6):881–7.CrossRefPubMedGoogle Scholar
- 13.von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GAJ, Hautvast RWM, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–23.CrossRefGoogle Scholar
- 14.• van der Heijden LC, et al. Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial. EuroIntervention. 2017;12(17):2128–31. This reference is 3-year follow-up data from the DUTCH PEERS trial showing in 1,807 patients (99.8%, four withdrawals) no difference in all-comers randomly assigned 1:1 to treatment with ZES versus EES. The primary endpoint was target vessel failure (TVF) and was a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularization. There were no differences between the ZES and EES groups with respect to TVF (10.7% vs. 10.3%; pLog-rank=0.77) or any of the subgroups: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank=0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank=0.87). In addition, the incidence of definite or probable stent thrombosis was also similar between the two groups for patients treated with ZES (1.4%) versus EES (1.1%; pLog-rank=0.66).CrossRefPubMedGoogle Scholar
- 15.• Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. Landmark trial of >9000 patients showing that extending DAPT beyond 12 months after DES implantation compared to aspirin alone significantly reduced the risks of stent thrombosis,major adverse cardiovascular and cerebrovascular events at the cost of an increased risk of bleeding.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.CrossRefPubMedPubMedCentralGoogle Scholar